About Josephine Taverna, M.D.
Dr. Josephine Taverna was born in Guadalajara, Mexico, and raised in New York City. She attended Yale College and majored in molecular biophysics and biochemistry. Dr. Taverna graduated from Mount Sinai School of Medicine and completed fellowship training in skin oncology, hematology oncology, cancer care and prevention, and drug development.
She’s a physician-scientist and her research is focused on harnessing single cell-omics from the bench to select targeted therapies for lung cancer patients. Over the past three years, she has been developing an independent research program in lung cancer therapeutics at the University of Texas Health Science Center San Antonio. In the thoracic oncology clinic, she has been enrolling patients with advanced lung cancer into clinical trials and provides them with novel therapies when standard treatments are no longer effective.
In the research lab, she has been conducting ex vivo drug experiments in organoids to mechanistically interrogate oncogenic pathways in lung adenocarcinoma cells and the tumor microenvironment network. This work is centered on the identification of potential biomarkers of treatment response, through which we can carefully select lung patients who will likely achieve long-term responses to novel targeted therapies.
- Assistant Professor, Division of Hematology Oncology, Department of Medicine with a Joint Appointment in Department of Molecular Medicine, University of Texas Health Science Center San Antonio
- American Board of Internal Medicine, Oncology
- American Board of Internal Medicine, Hematology
- Yale University, New Haven, CT
- University of Oxford, Oxford, England
- Medical School: Icahn School of Medicine at Mount Sinai, New York, NY
- Residency: University of Vermont College of Medicine, Akron, OH
- Boston University Medical Center, Boston, MA
- University of Arizona, Tucson, AZ
- University of Texas Health Science Center San Antonio, San Antonio, TX
- Locations & Contact
Research & Publications
Research & Publications
Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review.
Taverna JA, Yun S, Jonnadula J, Saleh A, Riaz IB, Abraham I, Yeager AM, Persky DO, McBride A, Haldar S, Anwer F.
Blood and Marrow Transplantation. 2016; 22(7):1182-96.
Double-blind, Randomized Trial of Different Letrozole Regimens in Postmenopausal Women with Increased Breast Cancer Risk – Effects on Estrogen Suppression and Associated Side Effects.
López AM, Pruthi S, Boughey JC, Perloff M, Hsu CH, Lang JE, Ley M, Frank D, Taverna JA, Chow HH.
Cancer Prev Res. Dec 14 2015.
Phosphodiestease 4 Inhibitors Augment Levels of Glucocorticoid Receptor in B Cell Chronic Lymphocytic Leukemia but Not in Normal Circulating Hematopoietic Cells.
Meyers JA, Taverna JA, Chaves J, Makkinje A, Lerner A.
Clin Cancer Res. 2007;13:4920-4927.
Infliximab as a Treatment for Idiopathic Hypereosinophilic Syndrome.
Taverna JA, Lerner A, Goldberg L, Demierre MF.
Arch Dermatol 2007;143(9):1110-1112.
Type of Cancer
Josephine Taverna M.D.
Patient-derived organoid model and circulating tumor cells for treatment response of lung cancer (CTMS 18-0056)
<p>Create a living biobank of PDOs from Stage I-III lung cancer patients.</p>